Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Staf van Reet | M | - |
DeuterOncology SA
 DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
| Serge Sagodira | M | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
| Els Hubloux | F | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
| Florence Wastelin | F | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | 1 years |
| Hélène Sabatel | F | - |
DeuterOncology SA
DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Belgium | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Timothy Perera
- Personal Network
